Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer.
Due to the fundamental progress in elucidating the molecular mechanisms of human diseases and the arrival of the post-genomic era, increasing numbers of therapeutic genes and cellular targets are available for gene therapy. Meanwhile, the most important challenge is to develop gene delivery vectors with high efficiency through target cell selectivity, in particular under in situ conditions. The most widely used vector system to transduce cells is based on adenovirus (Ad). Recent endeavors in the development of selective Ad vectors that target cells or tissues of interest and spare the alteration of all others have focused on the modification of the virus broad natural tropism. A popular way of Ad targeting is achieved by directing the vector towards distinct cellular receptors. Redirecting can be accomplished by linking custom-made peptides with specific affinity to cellular surface proteins via genetic integration, chemical coupling or bridging with dual-specific adapter molecules. Ideally, targeted vectors are incapable of entering cells via their native receptors. Such altered vectors offer new opportunities to delineate functional genomics in a natural environment and may enable efficient systemic therapeutic approaches. This review provides a summary of current state-of-the-art techniques to specifically target adenovirus-based gene delivery vectors.
Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Schillingallee 69, Rostock 18057, Germany. julia.reetz@uni-rostock.de.
Julia
J
Reetz
Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Schillingallee 69, Rostock 18057, Germany. der@uni-rostock.de.
Ottmar
O
Herchenröder
Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Schillingallee 69, Rostock 18057, Germany. brigitte.puetzer@med.uni-rostock.de.
Brigitte M
BM
Pützer
D000260:Adenoviruses, Human / Q000235:genetics / Q000502:physiology*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D010455:Peptides / Q000235:genetics / Q000378:metabolism*; D056189:Viral Tropism; D053585:Virus Attachment
D010455:Peptides